NASA Partners with Katalyst to Save Swift Observatory with Innovative Docking Mission 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change 
Eli Lilly Becomes First Pharma Giant to Hit $1 Trillion Amid Soaring Weight-Loss Drug Demand 
NASA Astronauts Wilmore and Williams Recover After Boeing Starliner Delay 
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy 
SK Hynix Considers U.S. ADR Listing to Boost Shareholder Value Amid Rising AI Chip Demand 
CDC Vaccine Review Sparks Controversy Over Thimerosal Study Citation 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
Shares of Neuren Pharmaceuticals Ltd (ASX:NEU) jumped over 10% on Thursday after the company announced a key development in its rare disease pipeline. The U.S. Patent and Trademark Office has approved Neuren’s patent application for NNZ-2591, a promising treatment targeting Pitt Hopkins syndrome (PTHS), a rare genetic neurological disorder with no approved therapies. The newly granted patent is valid until April 2040, giving Neuren long-term protection for the drug's use in treating PTHS.
This milestone adds to the momentum already behind NNZ-2591, which has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration (FDA). These regulatory advantages are designed to speed up the development and review process for treatments addressing serious or life-threatening conditions.
In a recent Phase 2 clinical trial, NNZ-2591 demonstrated significant potential, with 9 out of 11 children showing improvements in communication, cognitive function, and motor skills. Neuren is currently in discussions with the FDA to determine the next steps and is preparing to initiate a Phase 3 trial for a separate neurodevelopmental disorder, further expanding its pipeline.
As of 01:09 GMT, Neuren shares surged 11% to A$13.93 on the ASX, reaching their highest level in two weeks, reflecting strong investor confidence in the company’s R&D trajectory. Neuren already has one FDA-approved therapy—DAYBUE—for Rett syndrome, another rare neurodevelopmental disorder, reinforcing its position as a leading biotech in the field of pediatric neurology.
The patent approval for NNZ-2591 marks a significant advancement in Neuren’s efforts to bring novel treatments for underserved rare diseases to market, enhancing both its scientific credibility and market value.
